- funded by IMI-JU
- 01 March 2011 - 31 August 2016
- 11 EFPIA members
- 10 Academia and 5 SME's
- Total cost € 23,032,609
UCB Pharma is a global biopharma with operations in more than 40 countries. With a unique combination of expertise in biology and chemistry, UCB focuses on severe diseases in two therapeutic areas - CNS and Immunology. The Modelling & Simulation group, within the Global Exploratory Development, provides expertise in implementing model based drug development from preclinical through all phases of development.
The Modeling and Simulation group have expertise in all all activities related to translational PKPD modeling, the integration of in silico, in vitro and in vivo preclinical data with mechanism-based models to anticipate the effects of new drugs in humans. The group brings into the project its broad knowledge on model based drug development in the CNS and immunology areas and its experience/expertise in disease modeling and associated software development.